Condition
Organ Transplant Recipients
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Withdrawn2
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04642287Phase 2Withdrawn
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
NCT04329221Phase 2Withdrawn
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
NCT03438058CompletedPrimary
Complement-activating Anti-human Leucocyte Antigen Donor Specific Antibodies in Solid Organ Transplantation
NCT00829192Phase 2Unknown
Phase II AK Study in Organ Transplant Patients
Showing all 4 trials